CORPORATE MESSAGE - Max International Virtual Office

PRODUCT
Dr. Scott Nagasawa said that his father Herb recognized the value
of glutathione very early on, but also recognized the limitation of
the existing dietary supplements. He set out to find a way to vastly
improve the means for increasing glutathione levels in the body.
Much of Herb’s research centered on veterans who were prone to
liver disease resulting from a high incidence of alcohol abuse.
Developing RiboCeine TM
Herb found that low glutathione levels was common among veterans
with alcohol liver disease. He set out to find a solution. Knowing
that the fragile amino acid cysteine was essential to the production
of glutathione, he focused on finding ways to protect it during the
crucial absorption phase. He felt that if you protect the sulfhydryl
group on cysteine compounds and screen them for their ability to
increase glutathione you would significantly improve its bioavailability.
In two separate laboratories at the University of Minnesota and
the VA Medical Center in Minneapolis he and his team started to
synthesize dozens and dozens of sylfhydryl protected cysteine
compounds and screen them for their ability to increase glutathione
levels. Ribose, which is essential for the production of ATP, had the
best oral capabilities. When combined with cysteine ribose was by
far the most effective at increasing glutathione levels—thus the birth
of RiboCeine. One word summed it up for Dr. Nagasawa, “Eureka!”
This was an incredible breakthrough after years of dedicated work.
The first clinical study testing RiboCeine was conducted on mice,
since human clinical trials are cost prohibitive. To simulate the
damage cause by alcohol abuse, the mice were given high dose
acetaminophen, which in low doses is very safe. High doses,
however, deplete glutathione and cause liver damage. Nine
compounds, including RiboCeine and NAC (N-acetyl-l-cysteine),
were evaluated to determine their ability to protect against liver
toxicity. RiboCeine was the only compound administered where
no mice died. The mice administered RiboCeine, in fact, showed
a significant decrease in oxidative stress and no significant liver
damage. RiboCeine was shown to be 300 percent more effective
than NAC in the liver cell wall.
A separate study showed RiboCeine’s effectiveness in significantly
raising glutathione levels in all of the major organs of the body.
Dr. Nagasawa chose Max because he felt this company was the
best way to get his product to the corners of the earth. With the
release of MaxOne, this remarkable compound is now available for
human consumption for the first time in its pure form. The results
have already been felt by thousands of Max Associates who are
spreading the word about this revolutionary product. This is his
dream and a legacy Max Associates are mission-bound to make
a reality.
“It’s all up to us what we do with one man’s legacy and
vision,” Dave said. “It’s up to each of us to make the commitment
to carry it out.”
21